For the Inventor, By the Inventor

Enter assignee name

Beijing Innocare Pharma Tech Co., Ltd.

Calculating rank

USPTO Granted Patents = 15

% Expired Patents = 6.7

EPO Patents = 5

Trademarks = 3

Forward Citations = 5

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Xiangyang Chen (14 out of 20 patents)

Yingxiang Gao (6 out of 10 patents)

Yucheng Pang (5 out of 6 patents)

4. Norman Xianglong Kong (4 out of 7 patents)

5. Liqin Yu (2 out of 2 patents)

6. Zuopeng Wang (2 out of 2 patents)

7. Jing Feng (1 out of 34 patents)

8. Haihong Ni (1 out of 7 patents)

9. Chong Liu (1 out of 25 patents)

10. Chao Zhou (1 out of 8 patents)

11. Zhixiang Zheng (1 out of 3 patents)

12. Mark J Mulvihill (1 out of 3 patents)

15 patents: Sort by Forward Citations

1. 12617788 - Bridged bicyclic compounds as BTK inhibitors (2026-05-05),

2. 12391666 - Indoline-1-formamide compound, preparation method therefor, and medical use thereof (2025-08-19),

3. 12297188 - Crystalline forms of (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide (2025-05-13),

4. 12202813 - Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (2025-01-21),

5. 12178808 - Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (2024-12-31),

6. 11945792 - Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (2024-04-02),

7. 11878987 - Heterocyclic compound as TRK inhibitor (2024-01-23),

8. 11578058 - Heterocyclic compounds for inhibiting TYK2 activities (2023-02-14),

9. 11572353 - Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof (2023-02-07),

10. 11389445 - Pentafluorosulfanyl-substituted amide derivatives, preparation methods thereof and medical uses thereof (2022-07-19),

11. 11059805 - Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof (2021-07-13),

12. 11046682 - Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof (2021-06-29),

13. 10710981 - Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof (2020-07-14),

14. 10336755 - Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases (2019-07-02),

15. 9951056 - Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease (2018-04-24),

Company Overview

Beijing Innocare Pharma Tech Co., Ltd. is a biotechnology company specializing in the research, development, and manufacturing of innovative therapies for various medical conditions. The organization focuses on advancing treatments in oncology and autoimmune diseases, leveraging cutting-edge technologies to enhance patient outcomes. With a commitment to scientific excellence, Innocare Pharma aims to contribute significantly to the global healthcare landscape, particularly within the Chinese market and beyond.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

15 Patents

#201 in Beijing

#1,927 in China

#40,018 in the World

Beijing Innocare Pharma Tech Co., Ltd.

Forward Citations = 5

12 inventors:

Xiangyang Chen (14 out of 20 patents)

Yingxiang Gao (6 out of 10 patents)

Yucheng Pang (5 out of 6 patents)

4. Norman Xianglong Kong (4 out of 7 patents)

5. Liqin Yu (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Beijing Innocare Pharma Tech Co., Ltd.. Retrieved from https://idiyas.com/company/beijing-innocare-pharma-tech-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…